Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRLD Stock Price Chart Interactive Chart >
PRLD Price/Volume Stats
|Current price||$6.61||52-week high||$15.57|
|Prev. close||$6.67||52-week low||$3.87|
|Day high||$6.80||Avg. volume||180,805|
|50-day MA||$6.87||Dividend yield||N/A|
|200-day MA||$6.53||Market Cap||316.18M|
Prelude Therapeutics Inc. (PRLD) Company Bio
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Most Popular Stories View All
PRLD Latest News Stream
|Loading, please wait...|
PRLD Latest Social Stream
View Full PRLD Social Stream
Latest PRLD News From Around the Web
Below are the latest news stories about PRELUDE THERAPEUTICS INC that investors may wish to consider to help them evaluate PRLD as an investment opportunity.
Prelude Therapeutics Incorporated (NASDAQ:PRLD) drops to US$317m and insiders who purchased earlier this year lose another US$17k
The recent price decline of 15% in Prelude Therapeutics Incorporated's ( NASDAQ:PRLD ) stock may have disappointed...
Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Prelude Therapeutics (PRLD - Research Report) today and set a price target of $10.00. The company's shares opened today at $7.98.According to TipRanks, Hung is a 5-star analyst with an average return of 23.8% and a 56.52% success rate. Hung covers the Healthcare sector, focusing on stocks such as Rubius Therapeutics, Prelude Therapeutics, and Neurocrine.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prelude Therapeutics with a $13.00 average price target.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $16.49 and a one-year low of $3.87.
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0 million as of September 30, 2022, expected to fund multiple data catalysts with a runway into the fourth quarter of 2024 WILMINGTON, Del., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Synlogic (SYBX – Research Report), RVL Pharmaceuticals (RVLP – Research Report) and Prelude Therapeutics (PRLD – Research Report) with bullish sentiments. Synlogic (SYBX) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Synlogic, with a price target of $7.00. The company's shares closed last Tuesday at $1.08, close to its 52-week low of $0.83. According to TipRanks.
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid TumorsWILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration, (FDA) cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT3789, a first-in-class potent and selective SMARCA2 (BRM) protein degrader. The comp
PRLD Price Returns